The pharmacokinetics and blood-brain barrier permeation of the chelators 1,2 dimethyl-, 1,2 diethyl-, and 1-[ethan-1′ol]-2-methyl-3-hydroxypyridin-4-one in the rat

Toxicology

Volumn 108, Issue 3, 1996, Pages 191-199

  Fredenburg, Andrea M ^a   Sethi, Rajiv K ^a   Allen, David D ^b   Yokel, Robert A ^a,b  

^a UNIVERSITY OF KENTUCKY   (United States)

^b UNIVERSITY OF KENTUCKY MEDICAL CENTER   (United States)

Author keywords

1,2 diethyl 3 hydroxypyridin 4 one; 1,2 dimethyl 3 hydroxypyridin 4 one; 1 Ethan 1 ol 2 methyl 3 hydroxypyridin 4 one; 3 Hydroxypyridin 4 ones; Blood brain barrier; Chelator; CP20; CP40; CP94; Deferiprone; EL1NEt; L1

Indexed keywords

1,2 DIETHYL 3 HYDROXY 4 PYRIDONE; 3 HYDROXY 4 PYRIDONE DERIVATIVE; CHELATING AGENT; CP 40; DEFERIPRONE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ARTICLE; BLOOD; BLOOD BRAIN BARRIER; CONTROLLED STUDY; DRUG DISTRIBUTION; DRUG PENETRATION; FRONTAL CORTEX; INTRAVENOUS DRUG ADMINISTRATION; LATERAL BRAIN VENTRICLE; LIPOPHILICITY; MALE; MICRODIALYSIS; NONHUMAN; PHARMACOKINETICS; PRIORITY JOURNAL; RAT;

ANIMALS; BLOOD-BRAIN BARRIER; CEREBRAL VENTRICLES; CHELATING AGENTS; FRONTAL LOBE; IRON CHELATING AGENTS; MALE; MICRODIALYSIS; PYRIDONES; RATS; RATS, SPRAGUE-DAWLEY; SODIUM CYANIDE;

EID: 0030005823     PISSN: 0300483X     EISSN: None     Source Type: Journal    
DOI: 10.1016/0300-483X(95)03301-U     Document Type: Article

References (32)

1. Allen, D.D., Crooks, P.A. and Yokel, R.A. (1992) 4-Trimethylammonium antipyrine: a quaternary ammonium nonradionuclide marker for blood-brain barrier integrity during in vivo microdialysis. J. Pharmacol. Toxicol. Methods 28, 129-135.
2. Allen, D.D., Orvig, C. and Yokel, R.A. (1995) Evidence for energy-dependent transport of aluminum out of brain extracellular fluid. Toxicology 98, 31-39.
3. Allen, D.D. and Yokel, R.A. (1992) Dissimilar aluminum and gallium permeation of the blood-brain barrier demonstrated by in vivo microdialysis. J. Neurochem. 58, 903-908.
4. Alfrey, A.C. (1993) Aluminum toxicity in patients with chronic renal failure. Therap. Drug Monit. 15, 593-597.
5. Arze, R.S., Parkinson, I.S., Cartlidge, N.E.F., Britton, P. and Ward, M.K. (1981) Reversal of aluminum dialysis encephalopathy after desferrioxamine treatment. Lancet 2, 1116.
6. Bergeron, R.J., Streiff, R.R., Wiegand, J., Luchetta, G., Creary, E.A. and Peter, H.H. (1992) A comparison of the iron-clearing properties of 1,2-dimethyl-3-hydroxypyrid-4-one, 1,2,-diethyl-3-hydroxypyrid-4-one, and deferoxamine. Blood 79, 1882-1890.
7. Dobbin, P.S., Hider, R.C., Hall, A.D., Taylor, P.D., Sarpong, P., Porter, J.B., Xiao, G. and van der Helm, D. (1993) Synthesis, physicochemical properties, and biological evaluation of N-substituted 2-alkyl-3-hydroxy-4(1H)-pyridinones: orally active iron chelators with clinical potential. J. Med. Chem. 36, 2448-2458.
8. Epemolu, O.R., Singh, S., Hider, R.C. and Damani, L.A. (1992) The pharmacokinetics of 1,2-diethyl-3-hydroxypyridin-4-one (CP94) in rats. Drug Metab. Dispos. 20, 736-741.
9. Fox, J.L. and Lamson, M.L. (1989) RSTRIP: pharmacokinetic data stripping/least squares parameter optimization, Version 5. MicroMath, Inc., Salt Lake City, UT.
10. Fredenburg, A.M., Wedlund, P.J., Skinner, T.L., Damani, L.A., Hider, R.C. and Yokel, R.A. (1993) Pharmacokinetics of representative 3-hydroxypyridin-4-ones in rabbits: CP20 and CP94. Drug Metab. Dispos. 21, 255-258.
11. Gordeuk, V.R., Brittenham, G.M. and Thuma, P.E. (1994) Iron chelation as a chemotherapeutic strategy in the treatment of malaria. In: R.J. Bergeron and G. Brittenham (Eds), The Development of Iron Chelators for Clinical Use, CRC Press, Boca Raton, Florida, pp. 111-130.
12. Halliwell, B. (1994) Iron oxidative damage, and chelating agents. In: R.J. Bergeron and G. Brittenham (Eds), The Development of Iron Chelators for Clinical Use, CRC Press, Boca Raton, Florida, pp. 33-56.
13. Kontoghiorghes, G.J. (1993) Present status and future prospects of oral iron chelation therapy in thalassaemia and other diseases. Indian J. Pediatr. 60, 485-507.
14. Kontoghiorghes, G.J., Goddard, J.G., Bartlett, A.N. and Sheppard, L. (1990) Pharmacokinetic studies in humans with the oral iron chelator 1,2-dimethyl-3-hydroxypyrid-4-one. Clin. Pharmacol. Ther. 48, 255-261.
15. Kontoghiorghes, G.J., Barr, J. and Baillod, R.A. (1994) Studies of aluminum mobilization in renal dialysis patients using the oral chelator 1,2-dimethyl-3-hydroxypyrid-4-one. Arzneim-Forsch./Drug Res. 44, 522-526.
16. Leung, F.Y., Hodsman, A.B., Muirhead, N. and Henderson, A.R. (1985) Ultrafiltration studies in vitro of serum aluminum in dialysis patients after deferoxamine chelation therapy. Clin. Chem. 31, 20-23.
17. Matsui, D., Klein, J., Hermann, C., Grunau, V., McClelland, R., Chung, D., St. Louis, P., Olivieri, N. and Koren, G. (1991) Relationship between the pharmacokinetics and iron excretion pharmacodynamics of the new oral iron chelator 1,2-dimethyl-3-hydroxypyrid-4-one in patients with thalassemia. Clin. Pharmacol. Ther. 50, 294-298.
18. McLachlan, D.R.C. (1995) Aluminum and the risk for Alzheimer's disease. Environmetrics 6, 233-275.
19. McNamara, P.J., Fleishaker, J.C. and Hayden, T.L. (1987) Scientific note: mean residence time in peripheral tissue. J. Pharmacokinet. Biopharm. 15, 439-450.
20. Mehta, J., Singhal, S. and Mehta, B.C. (1995) Deferiprone in iron overload. N. Engl. J. Med. 333, 597-598.
21. Oldendorf, W.H. (1974) Lipid solubility and drug penetration of the blood brain barrier. Proc. Soc. Exp. Biol. Med. 147, 813-816.
22. Olivieri, N.F., Koren, G., Hermann, C., Bentur, Y., Chung, D., Klein, J., St. Louis, P., Freedman, M.H., McClelland, R.A. and Templeton D.M., (1990) Comparison of oral iron chelator L1 and desferrioxamine in iron-loaded patients. Lancet 336, 1275-1279.
23. Pippard, M.J. (1994) Iron chelation therapy in the treatment of iron overload. In: R.J. Bergeron and G. Brittenham (Eds), The Development of Iron Chelators for Clinical Use, CRC Press, Boca Raton, Florida, pp. 57-74.
24. Porter, J.B., Huehns, E.R. and Hider R.C. (1989) The development of iron chelating drugs. Baillere's Clin. Haematol. 2, 257-292.
25. Porter, J.B., Morgan, J., Hoyes, K.P., Burke, L.C., Huehns, E.R. and Hider, R.C. (1990) Relative oral efficacy and acute toxicity of hydroxypyridin-4-one iron chelators in mice. Blood 76, 2389-2396.
26. Rowland, M. and Tozer, T.N. (1989) Clinical Pharmacokinetics Concepts and Applications, Second Edition. Lea & Febiger, Philadelphia.
27. Skinner, T.L., Meurer, K.A. and Yokel, R.A. (1996) HPLC quantification of a very hydrophilic 3-hydroxypyridin-4-one chelator using a simple separation procedure and the baseline file subtraction method. J. Chromatogr. Sci. 34, 52-57.
28. Waldmeier, P.C., Buchle, A. and Steulet, A. (1993) Inhibition of catechol-o-methyltransferase (COMT) as well as tyrosine and tryptophan hydroxylase by the orally active iron chelator, 1,2-dimethyl-3-hydroxypyridin-4-one (L1, CP20), in rat brain in vivo. Biochem. Pharmacol. 45, 2417-2424.
29. Westlin, W.F. (1971) Deferoxamine as a chelating agent. Clin. Toxicol. 4, 597-602.
30. Yokel, R.A. Datta, A.K. and Jackson, E.G. (1991) Evaluation of potential aluminum chelators in vitro by aluminum solubilization ability, aluminum mobilization from transferrin and the octanol/aqueous distribution of the chelators and their complexes with aluminum. J. Pharmacol. Exp. Ther. 257, 100-106.
31. Yokel, R.A., Allen, D.D., Burgio, D.E. and McNamara, P.J., (1992) Antipyrine as a dialyzable reference to correct differences in efficiency among and within sampling devices during in vivo microdialysis. J. Pharmacol. Toxicol. Methods 27, 135-142.
32. Yokel, R.A., Fredenburg, A.M., Meurer, K.A. and Skinner, T.L. (1995) Influence of lipophilicity on the bioavailability and disposition of orally-active 3-hydroxypyridin-4-one metal chelators. Drug Metab. Dispos. 23, 1178-1180.